Open original FDA record ↗Recall record
- FDA identifier
- Z-1074-2025
- Company in FDA record
- Getinge Usa Sales Inc
- FDA classification date
- Feb 7, 2025
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class I
Reason stated in the source
Sevoflurane used with the vaporizer may degrade to hydrogen fluoride, which could present a risk to patients or health care providers through inhalation and/or skin exposure. Potential harms include irritation of respiratory tract, which in worst case may lead to lung edema and/or severe hypocalcemia, blistering, superficial ulceration, and/or hypomagnesemia.
Source facts
- Action
- Getinge notified consignees on 01/15/2024 via URGENT MEDICAL DEVICE RECALL letter. Consignees were provided additional information which is complementary to the existing user manual and were instructed to ensure all affected product inventory has been quarantined, consignees are entitled to credit/replacement, the recall information is forwarded to affected personnel and any customers if it was further distributed and complete and return the provided URGENT MEDICAL DEVICE RECALL RESPONSE FORM.
- Initiated
- 2025-01-15
- Root cause
- Device Design
- Distribution
- Domestic distribution to Kentucky and Connecticut.
- Recall number
- Z-1074-2025
- Recall status
- Open, Classified
- CDRH record ID
- 211958
- FDA classified
- 2025-02-07
- Recall event number
- 96083